Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
Baker S, Lechner L, Liu M, Chang JS, Cruz-Lim EM, Mou B, Jiang W, Bergman A, Schellenberg D, Alexander A, Berrang T, Bang A, Chng N, Matthews Q, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Arbour G, Yu I, Tyldesley S, Olson RA. Baker S, et al. Among authors: olson ra. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1497-1506. doi: 10.1016/j.ijrobp.2024.01.008. Epub 2024 Jan 12. Int J Radiat Oncol Biol Phys. 2024. PMID: 38220069 Clinical Trial.
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R, Mou B, Baker S, Chng N, Arbour G, Bergman A, Liu M, Schellenberg D, Matthews Q, Huang V, Mestrovic A, Hyde D, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Jiang W, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson RA. Eufemon Cereno R, et al. Among authors: olson ra. Radiother Oncol. 2023 May;182:109576. doi: 10.1016/j.radonc.2023.109576. Epub 2023 Feb 22. Radiother Oncol. 2023. PMID: 36822355 Clinical Trial.
Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA. Baker S, et al. Among authors: olson ra. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):849-855. doi: 10.1016/j.ijrobp.2022.08.026. Epub 2022 Oct 24. Int J Radiat Oncol Biol Phys. 2022. PMID: 36302495 Clinical Trial.
124 results